Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/22/2025

Oral Rehydration Therapy Administration

Indications for Nasogastric ORS Administration

  • The Centers for Disease Control and Prevention recommends continuous, slow nasogastric infusion of ORS via a feeding tube for patients who cannot tolerate oral intake but are not in shock, particularly helpful for children who are vomiting 1, 2
  • Nasogastric administration of ORS should be considered in infants, children, and adults with moderate dehydration who cannot tolerate oral intake 3
  • The World Health Organization suggests nasogastric ORS administration for children with normal mental status who are too weak or refuse to drink adequately 3
  • Patients with intractable vomiting may benefit from nasogastric ORS administration when small volumes administered every 1-2 minutes fail 1, 2
  • Infants unable to drink but not in shock may receive nasogastric ORS as an alternative to IV therapy when IV access is unavailable 4

Administration Protocol

  • The recommended rate for nasogastric ORS infusion is 15 mL/kg/hour, allowing for effective rehydration while minimizing vomiting 4, 1, 2
  • For patients with moderate dehydration, the total volume should be 100 mL/kg administered over 2-4 hours, delivered through the nasogastric tube at a steady rate 1, 5

Contraindications and Monitoring

  • Severe dehydration with shock or near-shock requires immediate IV rehydration, not nasogastric ORS administration 1, 2, 5
  • Altered mental status is a contraindication for nasogastric ORS administration due to the risk of aspiration 3
  • Intestinal ileus is a contraindication for oral fluids, including nasogastric ORS, until bowel sounds are audible 1, 2
  • Hydration status should be reassessed after 3-4 hours of nasogastric ORS therapy, and the infusion continued if the patient remains dehydrated 5
  • Once rehydrated and able to tolerate oral intake, patients should be transitioned to oral ORS administration 3